TransCode Therapeutics Inc (NASDAQ:RNAZ) price on Wednesday, February 05, rose 45.13% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $8.94.
A look at the stock’s price movement, the close in the last trading session was $6.16, moving within a range at $6.5701 and $12.7. The beta value (5-Year monthly) was 0.647. Turning to its 52-week performance, $66.33 and $2.66 were the 52-week high and 52-week low respectively. Overall, RNAZ moved 145.60% over the past month.
TransCode Therapeutics Inc’s market cap currently stands at around $6.23 million, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 300k for the company’s revenue for the quarter, with a low and high estimate of 300k and 300k respectively.
Turning to the stock’s technical picture we see that short term indicators suggest on average that RNAZ is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
RNAZ’s current price about 63.02% and 39.00% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 62.12, while 7-day volatility ratio is 38.27% and 40.15% in the 30-day chart. Further, TransCode Therapeutics Inc (RNAZ) has a beta value of 1.02, and an average true range (ATR) of 2.36.
If we refocus on TransCode Therapeutics Inc (NASDAQ:RNAZ), historical trading data shows that trading volumes averaged 6.58 over the past 10 days and 1.14 million over the past 3 months. The company’s latest data on shares outstanding shows there are 0.70 million shares.
The 0.12% of TransCode Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 23.92% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.74 million on 2024-10-31, giving us a short ratio of 0.5. The data shows that as of 2024-10-31 short interest in TransCode Therapeutics Inc (RNAZ) stood at 430.99999999999994 of shares outstanding, with shares short falling to 1.38 million registered in 2024-09-30. Current price change has pushed the stock 165.28% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RNAZ stock continues to rise going into the next quarter.
